X

Legal Notices

Disclaimer

ADVERTISING MATERIAL
The material contained on this Web site is provided for informational purposes only and does not constitute legal advice. The publication and receipt of any information contained on this Web site does not create an attorney-client relationship with Barash Law LLC or with any of our attorneys. Readers should not act upon any information on this site without seeking professional legal counsel. While the information on this Web site is maintained and periodically updated for accuracy, this information may contain omissions or errors for which we disclaim any and all liability.

Privacy Statement

Barash Law LLC does not collect identifying information from visitors to its Web site unless the information is provided by the visitor or the visitor's internet browser. We will only respond to direct inquiries, and will use information collected from internet browsers for the sole purpose of monitoring Web site usage. We do not share Web site data with outside third-parties. Barash Law LLC is not responsible for the privacy practices or content of any links to other Web sites contained in our Firm’s Web site. 

If you have any questions or concerns regarding this Privacy Statement, please contact us at info@ebarashlaw.com

Moving in the Right Direction: Cocrystals and the FDA

Read More

Using Solid Form Patents to Protect Pharmaceutical Products — Part I

Read More

Using Solid Form Patents to Protect Pharmaceutical Products — Part II

Read More

NEWS & EVENTS

EVENTS
IPWatchdog Webinar:
Drug Repositioning and Lifecycle Management: A Solid-Form Patent Strategy
December 1st, 2020
12:00-1:00PM EST
Eyal Barash of Barash Law LLC and Steef Boerrigter of AMRI SSCI, LLC will be speaking in a panel discussion webinar on December 1st at 12:00PM ET. The seminar will introduce the science behind solid forms and how they are protected as valuable intellectual property.
Register
EVENTS
AAPS eChalk Talk:
Surveying the Exclusivity and Patent Status of Remdesivir
January 28th, 2020
11:00AM EST
Remdesivir is the first approved therapy for COVID-19, having first received an Emergency Use Authorization and then finally full approval on October 22, 2020.  Asa fully approved drug, the FDA has provided the public with both regulatory exclusivity and patent information.  In this presentation, we will review that information, discuss what it means, and relate that to typical strategies used by innovator companies to protect valuable assets.
Registration Info Coming Soon

QUESTIONS ANSWERED

What is a solid form?

A solid form is the solid representation of a chemical compound.  Examples include polymorphs, salts, solvates, hydrates, cocrystals, and amorphous solids.

Read More
Why patent solid forms?

Solid forms are compositions of matter and Orange-Book listable as drug substance.  When the science is right, patenting follows.

Read More
How do you patent a solid form?

The same rules apply to solid forms as to any other inventions.  Careful attention should be paid to the kinds and quality of data used in solid form patents.

Read More

WHAT WE DO

pharmaceutical patents

Orange-Book Listable Patents Add Value

deals


Intellectual Property as Deal Currency

ip strategy and execution

A Strategy Requires a Realistic Plan

in-house
counsel

Legal Functionality as a Business Driver
© 2016 Barash Law LLC
Contact Us
Legal Notices